{"product_id":"astrazeneca-marketing-mix","title":"AstraZeneca Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAstraZeneca’s 4P mix blends innovative product pipelines, value-based pricing, global distribution partnerships, and targeted digital and medical promotions to sustain market leadership and patient access; the preview highlights key moves but the full 4Ps Marketing Mix Analysis unlocks actionable details, data, and editable slides to apply immediately—get the complete report for a ready-to-use strategic playbook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Portfolio Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstraZeneca sustains oncology leadership with Tagrisso, Lynparza, and Enhertu driving 2024 combined oncology revenue of about $19.5bn; by end-2025 the portfolio expanded to include next-gen antibody-drug conjugates (ADCs) and cell therapies for multiple solid tumors.\u003c\/p\u003e\n\u003cp\u003eThese high-value drugs target specific genetic mutations (EGFR, BRCA, HER2 variants) under precision medicine, aiming to raise median overall survival by months versus chemo in pivotal trials.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D spend on oncology rose to ~$6.2bn in 2024, supporting late-stage ADC and cell-therapy programs expected to contribute 10–15% of oncology sales by 2027.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical and CVRM Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFarxiga (dapagliflozin) anchors AstraZeneca’s Cardiovascular, Renal and Metabolism (CVRM) franchise, with 2024 sales of $8.6bn and double-digit growth driven by expansion into heart failure and chronic kidney disease indications; the CVRM strategy targets the diseases’ interconnected biology to enable holistic care, reduce hospitalization rates, and lower total cost of care; AstraZeneca also launched dual-action metabolic therapies in 2024 that cut pill burden and improved HbA1c reductions by ~0.7–1.1% in pivotal trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare Disease Specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca, after integrating Alexion in 2021, now markets a rare-disease portfolio led by Soliris (eculizumab) and Ultomiris (ravulizumab), serving small, high-need populations with conditions like PNH and aHUS; global rare-disease revenue hit about $6.3bn in 2024. By late 2025, AZ transitioned an estimated 65–75% of eligible patients to next‑gen formulations, improving dosing from biweekly to every 8 weeks for many, raising adherence and lowering infusion burden. These therapies target life‑threatening biology, supporting premium pricing and steady margin contribution within AZ’s Specialty Care segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory and Immunology Innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpastrazeneca respiratory and immunology product mix includes biologics fasenra tezspire which cut severe asthma exacerbations by in pivotal trials target patients unresponsive to inhaled corticosteroids global sales for the portfolio were about driven these brands.\u003e\n\u003cpcontinuous r is advancing inhaled combination therapies phase programs report improved fev1 expiratory volume gains of ml and better adherence via simplified devices supporting market expansion payer value cases.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFasenra\/Tezspire: ~50–60% exacerbation reduction\u003c\/li\u003e\n\u003cli\u003e2024 respiratory sales: ~$6.2B\u003c\/li\u003e\n\u003cli\u003eNew inhaled combos: +100–200 mL FEV1 in trials\u003c\/li\u003e\n\u003cli\u003eTarget: patients not helped by standard inhalers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcontinuous\u003e\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccines and Immune Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpastrazeneca has expanded vaccines and immune therapies beyond covid response to include long-acting monoclonal antibodies for viral protection targeting immunocompromised patients who fail standard vaccine responses these programs contributed az respiratory biologics revenue in\u003e\u003cpthe pipeline emphasizes durable protection vs evolving respiratory viruses using novel delivery platforms half-life antibodies inhaled formulations aiming to reduce hospitalization rates by up in high-risk cohorts per phase results.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-acting antibodies for immunocompromised\u003c\/li\u003e\n\u003cli\u003e$2.1B respiratory biologics revenue (2024)\u003c\/li\u003e\n\u003cli\u003ePhase 3: ~60% fewer hospitalizations in high-risk groups (2023)\u003c\/li\u003e\n\u003cli\u003eFocus: durable protection, novel delivery (extended half-life, inhaled)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca bets $6.2B oncology R\u0026amp;D to boost oncology share \u0026amp; slash respiratory hospitalizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca’s product mix in 2024–25 centers on oncology ($19.5B), CVRM\/Farxiga ($8.6B), respiratory biologics ($2.1B), and rare diseases ($6.3B), backed by $6.2B oncology R\u0026amp;D; next‑gen ADCs\/cell therapies and long‑acting antibodies aim to lift oncology share 10–15% by 2027 and cut hospitalizations ~60% in high‑risk respiratory cohorts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e$19.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVRM\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare\u003c\/td\u003e\n\u003ctd\u003e$6.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory biologics\u003c\/td\u003e\n\u003ctd\u003e$2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into AstraZeneca’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground recommendations for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses AstraZeneca’s 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, channel focus, and promotional levers—ideal for quick alignment, board briefings, or cross-functional planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstraZeneca runs a global manufacturing network across Europe, the Americas and Asia, producing specialty biologics and small molecules to keep supply steady; in 2024 the company reported \u0026gt;300,000 finished-dose batches and c.£6.2bn inventory-related assets to support distribution. The footprint reduces local disruption risk and maintains GMP quality; by 2025 AstraZeneca expanded localized manufacturing in 5 strategic regions, improving supply resilience and cutting lead times by an estimated 18%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Markets Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAstraZeneca has a strong emerging-markets presence, with China generating about 20% of group revenue in 2024 (~$8.6bn of $43bn), making it a key growth engine.\u003c\/p\u003e\n\u003cp\u003eLocalized distribution and partnerships with regional healthcare providers let AstraZeneca reach diverse patient groups across Asia, Latin America, and MENA, boosting access to oncology and CV therapies.\u003c\/p\u003e\n\u003cp\u003eGeographic diversity reduced reliance on Western markets, cutting revenue volatility; emerging markets grew ~12% CAGR 2021–24, helping balance risk and capture rising healthcare demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca uses specialized pharmacy networks for high-cost biologics and rare-disease drugs; these partners handled \u0026gt;$3.8B of specialty pharma distribution in 2024, supporting complex clinical supply chains.\u003c\/p\u003e\n\u003cp\u003eDistributors provide validated cold-chain logistics (2–8°C and −20°C control), reducing spoilage rates to under 0.5% and preserving product potency during transit to clinics or homes.\u003c\/p\u003e\n\u003cp\u003eHome delivery programs expanded 28% in 2024, improving adherence for temperature-sensitive therapies and lowering hospital-administered doses by 12% in pilot markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa large portion of astrazeneca oncology and immunology drugs biologic sales in sent directly to hospitals infusion centers ensuring availability at point-of-care supporting revenue reps medical science liaisons train clinical staff on administration safety protocols maintain uptake adherence.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% biologic hospital distribution (2024)\u003c\/li\u003e\n\u003cli\u003e$18.4bn oncology revenue (2024)\u003c\/li\u003e\n\u003cli\u003e350+ medical science liaisons globally\u003c\/li\u003e\n\u003cli\u003eDirect supply to infusion centers for critical care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Distribution and E-commerce\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpastrazeneca has upgraded digital distribution so healthcare providers can place orders via online portals with real-time inventory and automated replenishment cutting clinic admin time by an estimated reducing stockouts in pilot markets\u003e\n\u003cpby end-2025 these tools supported over markets routed of repeat orders and helped lower logistics cost per dose by making digital channels central to the global distribution network.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e25% less admin time\u003c\/li\u003e\n\u003cli\u003e18% fewer stockouts\u003c\/li\u003e\n\u003cli\u003e70+ markets onboarded by 2025\u003c\/li\u003e\n\u003cli\u003e45% of repeat orders via portals\u003c\/li\u003e\n\u003cli\u003e6% lower logistics cost per dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\u003c\/pastrazeneca\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAstraZeneca trims lead times 18%, slashes stockouts 18% and lowers logistics cost\/dose 6%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAstraZeneca maintains a global, localized manufacturing and cold-chain distribution network that supported \u0026gt;300,000 finished-dose batches and c.£6.2bn inventory assets in 2024, cut lead times ~18% by 2025, and routed 45% of repeat orders via digital portals across 70+ markets, reducing stockouts ~18% and logistics cost per dose ~6%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinished-dose batches\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;300,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory assets\u003c\/td\u003e\n\u003ctd\u003ec.£6.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina revenue share\u003c\/td\u003e\n\u003ctd\u003e~20% (~$8.6bn of $43bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology revenue\u003c\/td\u003e\n\u003ctd\u003e$18.4bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead time reduction\u003c\/td\u003e\n\u003ctd\u003e~18% (by 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat orders via portal\u003c\/td\u003e\n\u003ctd\u003e45% (70+ markets, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e~18% (pilot markets, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics cost per dose\u003c\/td\u003e\n\u003ctd\u003e~6% lower (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAstraZeneca 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual AstraZeneca 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises. It covers Product, Price, Place, and Promotion with actionable insights and strategic recommendations tailored to AZ’s portfolio and market dynamics. The file is the full, editable document ready for immediate use in presentations or reports. Buy with confidence—this is the final version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750228898169,"sku":"astrazeneca-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/astrazeneca-marketing-mix.png?v=1772223323","url":"https:\/\/matrixbcg.com\/products\/astrazeneca-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}